How can I simplify the regimen for a patient with mild cognitive impairment and major depressive disorder with sleep disturbance who is taking bupropion XL (bupropion) 300 mg, sertraline 100 mg, aripiprazole (Abilify) 2 mg, and melatonin 6 mg, given a pharmacogenomic report indicating reduced sertraline efficacy and sub‑therapeutic bupropion levels?

Medication Consolidation Strategy for MCI and MDD with Sleep Disturbance

Given the pharmacogenomic concerns and your patient's desire to reduce medications, discontinue sertraline and increase bupropion XL to 450 mg daily, while continuing aripiprazole 2 mg and melatonin 6 mg. This consolidates from four to three medications while addressing the GeneSight findings and maintaining therapeutic coverage for depression, sleep, and cognitive symptoms.

Rationale for This Approach

Why Discontinue Sertraline

The GeneSight report indicates reduced sertraline efficacy based on her pharmacogenomic profile. Second-generation antidepressants should be selected based on adverse effect profiles, cost, and patient preferences, as no antidepressant demonstrates superior efficacy over others 1. Since sertraline is pharmacogenomically problematic for this patient and she's already on bupropion (which targets different neurotransmitter systems), removing the redundant SSRI is logical.

Additionally, bupropion has significantly lower rates of sexual adverse events than sertraline 1, and sertraline is associated with higher rates of diarrhea, nausea, and somnolence compared to bupropion 1. For a patient with MCI, avoiding medications that cause somnolence is particularly important.

Why Increase Bupropion to 450 mg

The GeneSight report indicates sub-therapeutic bupropion levels at 300 mg. Bupropion at 300 mg daily has been shown effective for long-term treatment of recurrent major depression 2, but if her metabolism renders this dose insufficient, escalation is warranted. The FDA-approved maximum dose is 450 mg daily 3.

Bupropion XL demonstrated superior efficacy in treating decreased energy, pleasure, and interest—core symptoms of depression—and also improved insomnia domain scores 4. This is particularly relevant for your patient with sleep disturbances. A study comparing bupropion to SSRIs found that bupropion-treated remitters showed greater improvement in sleepiness and fatigue scores, with benefits evident from week 2 for sleepiness 5.

Why Continue Aripiprazole 2 mg

Low-dose aripiprazole (2.5 mg) combined with sertraline showed significantly better efficacy than sertraline alone, with improvement evident at weeks 1,2, and 4 6. Another study confirmed that aripiprazole augmentation of sertraline produced significantly greater improvement in depression scores 7.

Even after discontinuing sertraline, aripiprazole can augment bupropion. The combination addresses different neurotransmitter systems: bupropion targets norepinephrine and dopamine reuptake, while aripiprazole acts as a partial dopamine agonist and serotonin modulator. For patients with MCI, aripiprazole at low doses (2 mg) is generally well-tolerated 8, though monitor for akathisia, which occurred in 12.9% of patients on aripiprazole versus 3.4% on placebo 8.

Why Continue Melatonin 6 mg

Melatonin significantly improved cognitive function in adults with MCI when administered for 13-24 weeks between 20:30 and 21:00 9. A 2025 meta-analysis found that melatonin increased total sleep time by 12.4 minutes and improved Mini-Mental State Examination scores by 1.8 points in older adults with cognitive impairment 10. Given your patient has both MCI and sleep disturbances, melatonin addresses both conditions simultaneously.

The dose of 6 mg is appropriate—studies showing cognitive benefits used doses ranging from 3-10 mg 9, 10.

Implementation Algorithm

Week 1-2:

• Discontinue sertraline 100 mg immediately (no taper needed for this dose in most patients, though consider 2-week taper to 50 mg if she's been on it >8 weeks)
• Increase bupropion XL from 300 mg to 450 mg daily (take in morning to minimize insomnia risk 3)
• Continue aripiprazole 2 mg
• Continue melatonin 6 mg (administer between 20:30-21:00 9)

Week 2-4:

• Monitor for bupropion adverse effects: insomnia (16% incidence at 300 mg 3), anxiety (9% at 300 mg), tremor (3%), and agitation (9%)
• Assess for seizure risk factors, as bupropion may lower seizure threshold 3. Avoid if history of seizures or eating disorders
• Monitor blood pressure, as bupropion can cause hypertension 3

Week 6-8:

• Assess therapeutic response using standardized depression scales; if inadequate response after 6-8 weeks, modify treatment 1
• Evaluate sleep quality and cognitive function
• Monitor for akathisia from aripiprazole (use Barnes Akathisia Rating Scale if available)

Critical Caveats

Contraindications to bupropion 450 mg:

• History of seizures or eating disorders (absolute contraindications 3)
• Concurrent MAO inhibitor use or within 14 days 3
• Uncontrolled hypertension (monitor closely 3)

Pharmacogenomic considerations: While GeneSight indicates sub-therapeutic bupropion levels, the clinical utility of pharmacogenetic testing for dose adjustment remains under investigation 11. The dose increase to 450 mg is supported by FDA approval and clinical trials, not solely by the genetic test.

Switching versus augmentation: If this simplified regimen proves inadequate after 6-8 weeks, evidence shows no significant difference between switching to another antidepressant versus augmenting with additional agents 12, 13. At that point, consider switching bupropion to a different antidepressant (venlafaxine, escitalopram, or duloxetine) rather than adding back sertraline.

Depression severity monitoring: Assess patient status within 1-2 weeks of initiation for suicidal thoughts and behaviors, agitation, or unusual behavioral changes 1. This is particularly important during medication transitions.